User login
Key clinical point: Development of bacteremia in immunocompetent adult patients managed in the ICU for severe pneumococcal community-acquired pneumonia (CAP) had no effect on mortality.
Main finding: In-hospital mortality (21.5% vs. 16.9%; P = .11) or baseline variables associated with in-hospital death, such as the age ≥65 years (P interaction = .45) and bilateral pulmonary infection (P interaction = .77), were not significantly different between patients with and without bacteremia.
Study details: This was a post hoc analysis of the prospective STREPTOGENE study including 614 immunocompetent adult white patients admitted to an ICU for severe pneumococcal CAP. Of these, 270 patients had a positive blood culture for Streptococcus pneumoniae at admission.
Disclosures: The study was sponsored by 2 public health care and research agencies: the Assistance Publique Hôpitaux de Paris and Délégation à la Recherche Clinique et au Développement. None of the authors declared any conflict of interests.
Source: Bellut H et al. Ann Intensive Care. 2021;11:148 (Oct 24). Doi: 10.1186/s13613-021-00936-z.
Key clinical point: Development of bacteremia in immunocompetent adult patients managed in the ICU for severe pneumococcal community-acquired pneumonia (CAP) had no effect on mortality.
Main finding: In-hospital mortality (21.5% vs. 16.9%; P = .11) or baseline variables associated with in-hospital death, such as the age ≥65 years (P interaction = .45) and bilateral pulmonary infection (P interaction = .77), were not significantly different between patients with and without bacteremia.
Study details: This was a post hoc analysis of the prospective STREPTOGENE study including 614 immunocompetent adult white patients admitted to an ICU for severe pneumococcal CAP. Of these, 270 patients had a positive blood culture for Streptococcus pneumoniae at admission.
Disclosures: The study was sponsored by 2 public health care and research agencies: the Assistance Publique Hôpitaux de Paris and Délégation à la Recherche Clinique et au Développement. None of the authors declared any conflict of interests.
Source: Bellut H et al. Ann Intensive Care. 2021;11:148 (Oct 24). Doi: 10.1186/s13613-021-00936-z.
Key clinical point: Development of bacteremia in immunocompetent adult patients managed in the ICU for severe pneumococcal community-acquired pneumonia (CAP) had no effect on mortality.
Main finding: In-hospital mortality (21.5% vs. 16.9%; P = .11) or baseline variables associated with in-hospital death, such as the age ≥65 years (P interaction = .45) and bilateral pulmonary infection (P interaction = .77), were not significantly different between patients with and without bacteremia.
Study details: This was a post hoc analysis of the prospective STREPTOGENE study including 614 immunocompetent adult white patients admitted to an ICU for severe pneumococcal CAP. Of these, 270 patients had a positive blood culture for Streptococcus pneumoniae at admission.
Disclosures: The study was sponsored by 2 public health care and research agencies: the Assistance Publique Hôpitaux de Paris and Délégation à la Recherche Clinique et au Développement. None of the authors declared any conflict of interests.
Source: Bellut H et al. Ann Intensive Care. 2021;11:148 (Oct 24). Doi: 10.1186/s13613-021-00936-z.